These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24039233)

  • 41. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erythropoiesis-stimulating agents in anemia: use and misuse.
    Dharmarajan TS; Widjaja D
    J Am Med Dir Assoc; 2009 Nov; 10(9):607-16. PubMed ID: 19883882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New anemia therapies: translating novel strategies from bench to bedside.
    Macdougall IC
    Am J Kidney Dis; 2012 Mar; 59(3):444-51. PubMed ID: 22192713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
    Dharmarajan TS; Widjaja D
    Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
    Del Vecchio L; Locatelli F
    Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 47. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
    Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erythropoiesis-stimulating agents and heart failure.
    Lipšic E; van der Meer P; van Veldhuisen DJ
    Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenosine-5'-triphosphate-adenosine-glutathione cross-linked hemoglobin as erythropoiesis-stimulating agent.
    Simoni J; Simoni G; Moeller JF; Feola M; Griswold JA; Wesson DE
    Artif Organs; 2012 Feb; 36(2):139-50. PubMed ID: 22339724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents.
    Geisler BP
    Expert Opin Biol Ther; 2010 Aug; 10(8):1209-16. PubMed ID: 20557272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Erythropoietins in oncology.
    Lattanzi SC
    N Engl J Med; 2007 Sep; 357(12):1262; author reply 1262-3. PubMed ID: 17881762
    [No Abstract]   [Full Text] [Related]  

  • 53. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.
    Lyman GH
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):16-20. PubMed ID: 16925106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
    Fishbane S; Jhaveri KD
    Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erythropoiesis-stimulating agents--time for a reevaluation.
    Unger EF; Thompson AM; Blank MJ; Temple R
    N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
    [No Abstract]   [Full Text] [Related]  

  • 57. Cobalt metabolism and toxicology--a brief update.
    Simonsen LO; Harbak H; Bennekou P
    Sci Total Environ; 2012 Aug; 432():210-5. PubMed ID: 22732165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New treatment approaches in chronic kidney disease-associated anaemia.
    Del Vecchio L; Locatelli F
    Expert Opin Biol Ther; 2014 May; 14(5):687-96. PubMed ID: 24579747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
    Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke M; Weingart O; Kluge S; Piper M; Rades D; Steensma DP; Djulbegovic B; Fey MF; Ray-Coquard I; Machtay M; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
    Lancet; 2009 May; 373(9674):1532-42. PubMed ID: 19410717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anaemia in chronic heart failure].
    Hradec J
    Vnitr Lek; 2010 Aug; 56(8):854-9. PubMed ID: 20845618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.